GlaxoSmithKline
π¬π§United Kingdom
- Country
- π¬π§United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general med...
A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine When Given to Healthy Children 12 to 15 Months of Age
Phase 3
Not yet recruiting
- Conditions
- Interventions
- Biological: Investigational varicella vaccine_Lot 1Biological: Investigational varicella vaccine_Lot 2Biological: Investigational varicella vaccine_Lot 3Biological: Marketed varicella vaccine_Lot 1Biological: Marketed varicella vaccine_Lot 2Biological: MMR vaccineBiological: Hepatitis A vaccineBiological: PCV (pneumococcal conjugate vaccine) 13Biological: PCV 20Biological: Vaxneuvance
- First Posted Date
- 2024-12-18
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1840
- Registration Number
- NCT06740630
- Locations
- π¦πͺ
GSK Investigational Site, Abu Dhabi, United Arab Emirates
A Study to Evaluate the Safety, Tolerability, Blood Sample of Single Ascending Dose of GSK4771261 in Healthy Participants and Autosomal Dominant Polycystic Kidney Disease Participants
Phase 1
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-12-16
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 84
- Registration Number
- NCT06734234
- Locations
- π¬π§
GSK Investigational Site, Newcastle Upon Tyne, United Kingdom
A Study to Investigate the Long-term Safety and Efficacy of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease
- First Posted Date
- 2024-12-04
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 225
- Registration Number
- NCT06716606
- Locations
- πͺπΈ
GSK Investigational Site, VigoPontevedra, Spain
A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Effectiveness of GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors
Phase 1
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-11-28
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 73
- Registration Number
- NCT06710847
- Locations
- π³π±
GSK Investigational Site, Rotterdam, Netherlands
A Study to Assess the Potential for Airway Sensitivity Reactions With Propellants HFA-152a (Test) and HFA-134a (Reference) Administered Via Pressurized Inhalers in Adults With Mild Asthma
Phase 1
Not yet recruiting
- Conditions
- First Posted Date
- 2024-11-25
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 16
- Registration Number
- NCT06702462
- Locations
- πΊπΈ
GSK Investigational Site, San Antonio, Texas, United States
A Study on the Safety and Immune Response of a Urinary Tract Infection (UTI) Vaccine in Adults 18-64 Years of Age and Clinical Efficacy in Females 18-64 Years of Age
Phase 1
Recruiting
- Conditions
- First Posted Date
- 2024-11-25
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 448
- Registration Number
- NCT06702449
- Locations
- πͺπΈ
GSK Investigational Site, MOstoles, Spain
A Study on the Safety of an Investigational Chickenpox Vaccine, When Given to Healthy Children, 12 to 15 Months of Age
Phase 3
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-11-18
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 750
- Registration Number
- NCT06693895
- Locations
- π΅π±
GSK Investigational Site, Warszawa, Poland
A Study of an Investigational Flu Seasonal/SARS-CoV-2 Combination Vaccine in Adults
Phase 2
Recruiting
- Conditions
- Interventions
- Combination Product: SARS-CoV-2 mRNA Dose 1Combination Product: Flu Seasonal /SARS-CoV-2 mRNA Dose 1Combination Product: Flu Seasonal /SARS-CoV-2 mRNA Dose 2Combination Product: Licensed Flu SeasonalCombination Product: Flu Seasonal mRNACombination Product: SARS-CoV-2 mRNA Dose 2Drug: PlaceboCombination Product: Licensed COVID-19 mRNACombination Product: Phase 2 selected Investigational Flu Seasonal/SARS-CoV-2 mRNACombination Product: Phase 2 selected SARS-CoV-2 mRNA
- First Posted Date
- 2024-11-08
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 780
- Registration Number
- NCT06680375
- Locations
- πΊπΈ
GSK Investigational Site, Tomball, Texas, United States
A First-time in Human (FTIH) Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK4528287 in Healthy Participants
- First Posted Date
- 2024-11-08
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 48
- Registration Number
- NCT06681181
A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
Phase 3
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-11-07
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 520
- Registration Number
- NCT06679101
Β© Copyright 2024. All Rights Reserved by MedPath